BFC Planning’s Zevra Therapeutics ZVRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$16.6K Buy
1,510
+10
+0.7% +$119 ﹤0.01% 2140
2026
Q2
$21.5K Hold
1,500
– – ﹤0.01% 1976
2026
Q1
$14K Hold
1,500
– – ﹤0.01% 1878
2025
Q4
$13.4K Hold
1,500
– – ﹤0.01% 1937
2025
Q3
$14.3K Hold
1,500
– – ﹤0.01% 1744
2025
Q2
$13.2K Hold
1,500
– – ﹤0.01% 1684
2025
Q1
$11.2K Hold
1,500
– – ﹤0.01% 1717
2024
Q4
$12.5K Hold
1,500
– – ﹤0.01% 1661
2024
Q3
$10.4K Buy
+1,500
New +$10.2K ﹤0.01% 1726

Other funds holding ZVRA

BFC Planning's ZVRA Position: Q3 2026 in Review

BFC Planning increased its Zevra Therapeutics (ZVRA) stake by 0.67% in Q3 2026, buying an estimated $119 and bringing the position to 1,510 shares worth $16.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2140.

BFC Planning first reported a position in ZVRA in Q3 2024 and has held it in 9 quarters since. The position peaked at $21.5K in Q2 2026. 131 funds tracked by Wall St. Rank hold ZVRA as of Q3 2026.

  • BFC Planning held 1,510 shares of Zevra Therapeutics worth $16.6K as of Q3 2026.
  • BFC Planning bought 10 Zevra Therapeutics shares in Q3 2026, an estimated $119.
  • Zevra Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2140 holding.
  • BFC Planning first reported a position in Zevra Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's Zevra Therapeutics position peaked at $21.5K in Q2 2026.
  • 131 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.